A reduction rate of AFP was significantly correlated with posttransplant mortality or HCC recurrence rates after LT.20 The same group clarified the efficacy of USCF downstaging criteria compared with patients who had an initial tumor burden exceeding USCF criteria.21 Vutien et al22 advocated a useful tool for evaluating risk for recurrent HCC after LT by classifying HCC burden as Milan and UCSF criteria at initial, maximum, and last exception petition. The gene discussed is AFP; the disease is hepatocellular carcinoma.